StemX Bio's revolutionary human in vitro 3D pancreatic model will completely transform the area of diabetes drug discovery. This innovative approach directly addresses the critical unmet need within the diabetes research community for more accurate and physiologically relevant in vitro models.

To become the new standard in vascular treatment. By bringing regenerative capacity for the first time to a stent, a wide range of clinical applications will benefit from our innovative approach.

T Cell Factory (TCF) will identify and develop therapeutic T cell receptor (TCR) genes for the growing market of cancer therapies.

We at TargED have developed MICROLYSE, an innovative fusion-protein that has an antibody domain that recognizes microthrombi and an enzymatic domain that breaks them down.

thromboDx BV is a molecular diagnostics company that develops and commercialises blood-based diagnostics through its proprietary platelet-powered technology platform

At Toxys we strongly believe in bringing high quality information to our partners and clients. I strongly believe that the future for human safety assessment is not with simple tests that only provide a yes or no answers, but advanced in vitro models that provide reliable and relevant insight into the mechanism of action of novel chemicals and materials. We are committed to support our partners in understanding their latest compounds and in making the right decisions during R&D of novel products

At TrianecT, we develop StrokePointer: a fast pre-hospital solution for early stroke diagnosis.

TropIQ Health Sciences accelerates the discovery and development of drugs against malaria.

TubaSCAN for Chlamydia trachomatis associated infertility and tubal pathology based on host genetic markers.

drug discovery in the ubiquitin field